{"id":"hycanthone","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"DNA-(apurinic or apyrimidinic site) lyase","category":"target"},{"label":"APEX1","category":"gene"},{"label":"Active","category":"status"},{"label":"Anthelmintics","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antiparasitic Agents","category":"pharmacology"},{"label":"Antiplatyhelmintic Agents","category":"pharmacology"},{"label":"Schistosomicides","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"hycanthon","offLabel":[],"synonyms":["hycanthone","hycanthon"],"timeline":[],"approvals":[],"brandName":"Hycanthon","ecosystem":[],"mechanism":{"target":"DNA-(apurinic or apyrimidinic site) lyase","targets":[{"gene":"APEX1","source":"DrugCentral","target":"DNA-(apurinic or apyrimidinic site) lyase","protein":"DNA-(apurinic or apyrimidinic site) lyase"}],"modality":"Small Molecule","explanation":"Imagine your DNA is a long, fragile ladder. When the ladder gets damaged, Hycanthon helps the cell's repair machinery to fix the breaks, preventing further damage and potential cancer. This process is crucial for maintaining the integrity of our genetic material.","oneSentence":"Hycanthon works by stabilizing the DNA damage response to allow cells to repair DNA breaks.","technicalDetail":"Hycanthon targets DNA-(apurinic or apyrimidinic site) lyase, an enzyme involved in the base excision repair pathway, which is responsible for repairing DNA damage caused by oxidative stress, alkylation, and deamination."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1383","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HYCANTHONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T13:52:52.836816","biosimilars":[],"competitors":[{"drugName":"mitoxantrone","drugSlug":"mitoxantrone","fdaApproval":"1987-12-23","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"hycanthone","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"mitoxantrone","brandName":"mitoxantrone","genericName":"mitoxantrone","approvalYear":"1987","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"2BXX5EVN2A","CHEBI":"CHEBI:52768","INN_ID":"2207","UMLSCUI":"C0020207","ChEMBL_ID":"CHEMBL22077","KEGG_DRUG":"D00541","DRUGBANK_ID":"DB14061","PDB_CHEM_ID":" QHM","PUBCHEM_CID":"3634","MESH_DESCRIPTOR_UI":"D006826"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":327,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Hycanthon (HYCANTHONE) is a small molecule modality targeting DNA-(apurinic or apyrimidinic site) lyase. Its mechanism involves stabilizing the DNA damage response, allowing cells to repair DNA breaks. However, specific details about its commercial status, approved indications, and pharmacokinetic properties are not available. Further research is needed to understand its potential therapeutic applications and safety profile. As a result, Hycanthon's clinical utility remains unclear.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}